Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02633007 · ClinicalTrials.gov registry record · Phase 1

A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma

A Phase 1 study of Asthma, sponsored by Acorda Therapeutics.

Completed
Registry status
Phase 1
Development phase
25
Enrollment target
3
Study locations

NCT02633007: Completed Phase 1 study of Asthma, sponsored by Acorda Therapeutics.

NCT02633007 is a Phase 1 study of Asthma that has completed, run by Acorda Therapeutics. The registered enrollment target is 25 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02633007, a Phase 1 study of Asthma, has completed, sponsored by Acorda Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
25 participants
Enrollment target
3
Study locations

Study Summary

This study is a double-blind, randomized, placebo-controlled, 2-period, crossover study to evaluate safety and PK of 3 doses of CVT 301 levodopa (l-dopa) in adults with asthma.

Primary Outcome

Pulmonary function will be measured by spirometry using the guideline specified by the Third National Health and Nutrition Examination Survey (NHANES III)

Conditions Studied

Interventions

  • OTHER Placebo
  • DRUG Carbidopa
  • DRUG CVT-301 (levodopa inhalation powder)

Study Locations (3)

Florida

  • Site 002 - Daytona Beach

Massachusetts

  • Site 001 - North Dartmouth

Texas

  • Site 003 - Dallas

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2015-12
Est. Completion 2016-05
Phase Phase 1
Acorda Therapeutics

36 total trials

What the finished NCT02633007 record still lists

NCT02633007 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT02633007 reports a single indexed study location in Florida, Massachusetts, Texas.

Frequently Asked Questions

What is clinical trial NCT02633007 about?

NCT02633007 is a clinical study titled "A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma". This study is a double-blind, randomized, placebo-controlled, 2-period, crossover study to evaluate safety and PK of 3 doses of CVT 301 levodopa (l-dopa) in adults with asthma.

What is the current status of trial NCT02633007?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2015-12. Estimated completion is 2016-05.

What conditions does trial NCT02633007 study?

This clinical trial studies the following conditions: Asthma.

What interventions are being tested in trial NCT02633007?

The interventions under investigation include: Placebo (OTHER), Carbidopa (DRUG), CVT-301 (levodopa inhalation powder) (DRUG).

Who is sponsoring clinical trial NCT02633007?

This trial is sponsored by Acorda Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02633007 being conducted?

This trial has 3 study locations across Florida, Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02633007's enrollment target sits among peer trials

25 318th of 374 higher than 50 of 374 other Asthma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01166854 · 25 participants

    Characterization of Familial Myopathy and Paget Disease of Bone

  • NCT01913106 · 25 participants · Phase 1

    HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

  • NCT02138669 · 25 participants · NA

    Intacs Prescription Inserts for Keratoconus Patients

  • NCT02174549 · 25 participants · Phase 1

    Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02633007, the US trial registry maintained by the National Library of Medicine. NCT02633007 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.